Phaseline

Companies › Neowise Biotechnology

Neowise Biotechnology: clinical trials, targets and expected readouts

1 active drug program in 1 registered trial: 1 Phase 1; Oncology; next expected readout Dec 2028.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
NW-101C
PRAME-targeted TCR-engineered T cells
PRAMEPhase 1Solid Metastatic TumorDec 2028

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT07266298NW-101CPhase 1Solid Metastatic TumorOncologyDec 2028

Targets

PRAME (1)

Companies with the same targets

Immunocore PDC*line Pharma SAS Immatics US

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.